PRC2-INHIBITOREN
European patent · EP4043466 · In force
Register entry
- Publication number
- EP4043466
- Application number
- EP22165237
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Jan 29, 2019
- Published
- Aug 17, 2022
- Granted
- Aug 21, 2024
- Protection ends at the latest
- Jan 28, 2039
- Next annual fee due
- Jan 31, 2027
- IPC classes
- C07D 487/04 (2006.01)A61P 35/00 (2006.01)A61K 31/519 (2006.01)
- Priority
- US 201862624176 P 31.01.2018US 201862672701 P 17.05.2018US 201862747736 P 19.10.2018
- Divided from
- EP19710816
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Feb 1, 2026
Change
Published in Swissreg on 01.02.2026
- Jul 2, 2025
Change
Published in Swissreg on 02.07.2025
- Feb 1, 2025
Change
Published in Swissreg on 01.02.2025
- Oct 29, 2024
Holder’s address changed
- Owner
- Mirati Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121, USA → Mirati Therapeutics, Inc., Route 206 and Province Line Road, Princeton, New Jersey 08543, USA
Published in Swissreg on 29.10.2024
- Sep 19, 2024
Agent entered
- Representative
- MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex
Published in Swissreg on 19.09.2024
- Aug 21, 2024
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 21.08.2024
Parties
Inventor
Del Mar 92014, US
San Diego 92111, US
San Diego 92130, US
San Diego 92130, US
San Diego 92128, US
San Diego 92127, US
San Diego 92122-4647, US
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.